Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 7/20 | 0.80 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.80 |
| ▸ | NT5E | P21589 | 1/20 | 0.80 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.74 |
| ▸ | UMPS | P11172 | 3/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686864 | 1.00 | P2RY6 (0.80) | P2RY6P2RY14NT5EDNPH1UMPS | |
| SCHEMBL465109 | 1.00 | P2RY6 (0.80) | P2RY6P2RY14NT5EDNPH1UMPS | |
| Lithium Ion SCHEMBL29357540 | 0.99 | P2RY6 (0.79) | P2RY6P2RY14NT5EDNPH1UMPS | |
| SCHEMBL9702618 | 0.91 | P2RY6 (0.74) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL9702628 | 0.91 | P2RY6 (0.74) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL28741430 | 0.91 | P2RY6 (0.74) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL9551479 | 0.91 | P2RY6 (0.77) | P2RY6P2RY14NT5EDNPH1TSHR | |
| SCHEMBL10932987 | 0.91 | P2RY6 (0.77) | P2RY6P2RY14NT5EDNPH1TSHR | |
| SCHEMBL148676 | 0.90 | P2RY6 (0.73) | P2RY6P2RY14NT5EDNPH1P2RY2 | |
| SCHEMBL148675 | 0.90 | P2RY6 (0.73) | P2RY6P2RY14NT5EDNPH1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021260322-A1 | STRAINS OF CLOSTRIDIUM BACTERIA RESISTANT TO 5-FLUOROURACIL, GENETIC TOOLS AND USES THEREOF | IFP Energies Nouvelles (FR) | 2021-12-30 | — | — | WO | claimed |
| EP-0791056-B1 | LIPID-CLEAVAGE ENZYME COMPLEX | HEIDELBERG PHARMA GMBH (DE) | 2005-03-30 | — | — | EP | claimed |
| US-20030082167-A1 | Lapid cleavage enzyme | HEIDELBERG PHARMA HOLDING GMBH | 2003-05-01 | — | — | US | claimed |
| US-20020106363-A1 | LIPID CLEAVAGE ENZYME | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2002-08-08 | — | — | US | claimed |
| EP-0302473-B1 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | BRISTOL MYERS SQUIBB CO (US) | 1995-02-15 | — | — | EP | claimed |
| US-4975278-A | Converting the prodrug at the tumor site to the active drug by means of the conjugate bound to a tumor surface antigen | BRISTOL-MYERS COMPANY (US) | 1990-12-04 | — | — | US | claimed |
| EP-0302473-A2 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | Bristol-Myers Squibb Company (US) | 1989-02-08 | — | — | EP | claimed |
| JP-53029937-A | — | — | None | — | — | JP | disclosed |
| JP-53031677-A | — | — | None | — | — | JP | disclosed |
| EP-4696780-A1 | METHOD FOR TRANSFORMING BACTERIUM BELONGING TO GENUS BIFIDOBACTERIUM | Kabushiki Kaisha Yakult Honsha (JP) | 2026-02-18 | — | — | EP | disclosed |
| EP-4689059-A1 | MODIFIED CLOSTRIDIUM BACTERIA, GENETIC EDITING TOOL FOR THE PSOL PLASMID OF CLOSTRIDIUM BACTERIA AND USES THEREOF | IFP Energies nouvelles (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4689128-A1 | NUCLEIC ACID MOLECULE AND METHODS | Forge Genetics Ltd (GB) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024209201-A1 | NUCLEIC ACID MOLECULE AND METHODS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2024-10-10 | — | — | WO | disclosed |
| US-5552440-A | Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0302473-B1 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | BRISTOL MYERS SQUIBB CO (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0540859-A1 | Anthracycline prodrugs | Bristol-Myers Squibb Company (US) | 1993-05-12 | — | — | EP | disclosed |
| US-4975278-A | Converting the prodrug at the tumor site to the active drug by means of the conjugate bound to a tumor surface antigen | BRISTOL-MYERS COMPANY (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0302473-A2 | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | Bristol-Myers Squibb Company (US) | 1989-02-08 | — | — | EP | disclosed |
| JP-S5331677-A | 5-FLUOROURIDYLIC ACID DERIVATIVES AND THEIR PREPARATION | MITSUI TOATSU CHEM INC | 1978-03-25 | — | — | JP | disclosed |
| JP-S5329937-A | CARCINOSTATIC AGENT | MITSUI TOATSU CHEM INC | 1978-03-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082167-A1 | Lapid cleavage enzyme | LAP3, NAALAD2, ENGASE | P2RY6 3635/4885P2RY14 2861/4885NT5E 621/4885 |
| US-20020106363-A1 | LIPID CLEAVAGE ENZYME | SMPD1, MMEL1, ENGASE | P2RY6 3422/4885P2RY14 2684/4885NT5E 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.